These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Zhou Z; Lafleur EA; Koshkina NV; Worth LL; Lester MS; Kleinerman ES Mol Cancer Res; 2005 Dec; 3(12):685-91. PubMed ID: 16380506 [TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516 [TBL] [Abstract][Full Text] [Related]
5. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex. Huang L; Shitashige M; Satow R; Honda K; Ono M; Yun J; Tomida A; Tsuruo T; Hirohashi S; Yamada T Gastroenterology; 2007 Nov; 133(5):1569-78. PubMed ID: 17983804 [TBL] [Abstract][Full Text] [Related]
6. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2. Harris LN; Yang L; Tang C; Yang D; Lupu R Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896 [TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells. Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696 [TBL] [Abstract][Full Text] [Related]
8. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity. Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921 [TBL] [Abstract][Full Text] [Related]
9. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Chen S; Gomez SP; McCarley D; Mainwaring MG Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828 [TBL] [Abstract][Full Text] [Related]
10. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia. Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416 [TBL] [Abstract][Full Text] [Related]
11. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta. Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262 [TBL] [Abstract][Full Text] [Related]
12. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806 [TBL] [Abstract][Full Text] [Related]
13. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex. Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981 [TBL] [Abstract][Full Text] [Related]
14. Modulation of DNA topoisomerase II alpha promoter activity by members of the Sp (specificity protein) and NF-Y (nuclear factor Y) families of transcription factors. Magan N; Szremska AP; Isaacs RJ; Stowell KM Biochem J; 2003 Sep; 374(Pt 3):723-9. PubMed ID: 12769819 [TBL] [Abstract][Full Text] [Related]
15. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death. Emmons M; Boulware D; Sullivan DM; Hazlehurst LA Biochem Pharmacol; 2006 Jun; 72(1):11-8. PubMed ID: 16678798 [TBL] [Abstract][Full Text] [Related]
16. Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells. Takano H; Ise T; Nomoto M; Kato K; Murakami T; Ohmori H; Imamura T; Nagatani G; Okamoto T; Ohta R; Furukawa M; Shibao K; Izumi H; Kuwano M; Kohno K Anticancer Drug Des; 1999 Apr; 14(2):87-92. PubMed ID: 10405635 [TBL] [Abstract][Full Text] [Related]
17. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer. Withoff S; van der Zee AG; de Jong S; Hollema H; Smit EF; Mulder NH; de Vries EG Br J Cancer; 1999 Feb; 79(5-6):748-53. PubMed ID: 10070864 [TBL] [Abstract][Full Text] [Related]
18. Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity. Hirota H; Gosky D; Berger NA; Chatterjee S Int J Oncol; 2002 Feb; 20(2):311-8. PubMed ID: 11788894 [TBL] [Abstract][Full Text] [Related]
19. Topoisomerase IIalpha inhibition following DNA transfection greatly enhances random integration in a human pre-B lymphocyte cell line. Toyoda E; Kurosawa A; Kamekawa H; Adachi N Biochem Biophys Res Commun; 2009 May; 382(3):492-6. PubMed ID: 19285952 [TBL] [Abstract][Full Text] [Related]
20. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase. Sakaguchi A; Kikuchi A J Cell Sci; 2004 Mar; 117(Pt 7):1047-54. PubMed ID: 14996935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]